the previous week. There were certain important technical issues 
left unresolved at the October 3 RAC meeting that necessitate the 
subcommittee’s further review of the data submitted in support of 
this project. It is the responsibility of NIH and the RAC to 
address these issues, without causing unreasonable delay. I am 
certain that the review will proceed as expeditiously as 
possible . 
Sincerely yours, 
/s/ James B. Wyngaarden 
James B. Wyngaarden, M.D. 
Director 
Recombinant DNA Research, Volume 13 
[451] 
